Amgen Q2 Earnings Beat Estimates, Shares Fall Amid MariTide Focus
PorAinvest
miércoles, 6 de agosto de 2025, 2:21 pm ET1 min de lectura
AMGN--
Key highlights of the quarter include:
- Product Sales Growth: Fifteen products experienced double-digit sales growth, with Repatha® (evolocumab) and EVENITY® (romosozumab-aqqg) leading the way, increasing by 31% and 32% YoY, respectively [1].
- Operating Income and Margin: GAAP operating income rose from $1.9 billion to $2.7 billion, while the operating margin increased 6.6 percentage points to 30.3% [1].
- Non-GAAP Metrics: Non-GAAP EPS increased 21% to $6.02, and non-GAAP operating income rose to $4.3 billion, with the operating margin expanding 0.7 percentage points to 48.9% [1].
- Free Cash Flow: The company generated $1.9 billion in free cash flow, down from $2.2 billion in the previous year, primarily due to deferred tax payments and higher capital expenditures [1].
Amgen also raised its full-year 2025 adjusted earnings guidance to $20.20-$21.30 per share and sales outlook to $35-$36 billion [1]. However, investor focus remains on the experimental weight-loss drug MariTide, with data readout anticipated in the fourth quarter of 2025 [1].
Despite the positive results, Amgen shares are trading lower by 5.10% to $284.97 as of July 2, 2025, reflecting market concerns about the potential impact of biosimilar competition and the upcoming MariTide data readout [1].
References:
[1] Amgen Reports Second Quarter 2025 Financial Results. (2025, August 5). PRNewswire. Retrieved from https://www.amgen.com/newsroom/press-releases/2025/08/amgen-reports-second-quarter-2025-financial-results
Amgen reported Q2 earnings of $6.02 per share, up 21% YoY, beating expectations. Sales rose 9% to $9.18 billion, exceeding estimates. The company raised FY25 adjusted earnings guidance to $20.20-$21.30 and sales outlook to $35-$36 billion. Despite positive results, investor focus remains on experimental weight-loss drug MariTide, with data readout anticipated in Q4 2025. Amgen shares are trading lower by 5.10% to $284.97.
Amgen (NASDAQ: AMGN) announced its second-quarter 2025 financial results, showcasing robust performance across various therapeutic areas. The company reported earnings per share (EPS) of $6.02, up 21% year-over-year (YoY), exceeding analysts' expectations of $5.75 [1]. Total revenues increased 9% to $9.2 billion, driven by 13% volume growth, partially offset by a 3% decrease in net selling price [1].Key highlights of the quarter include:
- Product Sales Growth: Fifteen products experienced double-digit sales growth, with Repatha® (evolocumab) and EVENITY® (romosozumab-aqqg) leading the way, increasing by 31% and 32% YoY, respectively [1].
- Operating Income and Margin: GAAP operating income rose from $1.9 billion to $2.7 billion, while the operating margin increased 6.6 percentage points to 30.3% [1].
- Non-GAAP Metrics: Non-GAAP EPS increased 21% to $6.02, and non-GAAP operating income rose to $4.3 billion, with the operating margin expanding 0.7 percentage points to 48.9% [1].
- Free Cash Flow: The company generated $1.9 billion in free cash flow, down from $2.2 billion in the previous year, primarily due to deferred tax payments and higher capital expenditures [1].
Amgen also raised its full-year 2025 adjusted earnings guidance to $20.20-$21.30 per share and sales outlook to $35-$36 billion [1]. However, investor focus remains on the experimental weight-loss drug MariTide, with data readout anticipated in the fourth quarter of 2025 [1].
Despite the positive results, Amgen shares are trading lower by 5.10% to $284.97 as of July 2, 2025, reflecting market concerns about the potential impact of biosimilar competition and the upcoming MariTide data readout [1].
References:
[1] Amgen Reports Second Quarter 2025 Financial Results. (2025, August 5). PRNewswire. Retrieved from https://www.amgen.com/newsroom/press-releases/2025/08/amgen-reports-second-quarter-2025-financial-results
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios